Is Febuxostat Use Associated With Increased Risk of Cardiovascular Disease Events? The Answer Is Crystal Clear

被引：2
作者：
Charlton, Alexandra [1 ,2 ]
MacMullan, Paul Anthony [1 ]
机构：
[1] Univ Calgary, Cumming Sch Med, Div Rheumatol, Dept Med, Calgary, AB, Canada
[2] Univ Calgary, Cumming Sch Med, Div Rheumatol, Dept Med,Pharm, Calgary, AB, Canada
来源：
JOURNAL OF RHEUMATOLOGY | 2021年 / 48卷 / 07期
关键词：
HYPERURICEMIA;
D O I：
10.3899/jrheum.201304
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：965 / 966
页数：2
相关论文
共 21 条
[1]  
Al-Abdouh Ahmad, 2020, Mayo Clin Proc Innov Qual Outcomes, V4, P434, DOI 10.1016/j.mayocpiqo.2020.04.012
[2]  
[Anonymous], Dabigatran-Ibuprofen-ASA-Ibuprofen. Interactions. Lexicomp
[3]   Gout: optimizing treatment to achieve a disease cure [J].
Antonio Bernal, Jose ;
Quilis, Neus ;
Andres, Mariano ;
Sivera, Francisca ;
Pascual, Eliseo .
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2016, 7 (02) :135-144
[4]   The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial [J].
Becker, Michael A. ;
Schumacher, H. Ralph ;
Espinoza, Luis R. ;
Wells, Alvin F. ;
MacDonald, Patricia ;
Lloyd, Eric ;
Lademacher, Christopher .
ARTHRITIS RESEARCH & THERAPY, 2010, 12 (02)
[5]  
BMJ Practice, WHAT IS GRADE
[6]   Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis [J].
Cuenca, John A. ;
Balda, Javier ;
Palacio, Ana ;
Young, Larry ;
Pillinger, Michael H. ;
Tamariz, Leonardo .
INTERNATIONAL JOURNAL OF RHEUMATOLOGY, 2019, 2019
[7]   Febuxostat Use and Risks of Cardiovascular Disease Events, Cardiac Death, and All-cause Mortality: Metaanalysis of Randomized Controlled Trials [J].
Deng, Hao ;
Zhang, Bao Long ;
Tong, Jin Dong ;
Yang, Xiu Hong ;
Jin, Hui Min .
JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) :1082-1089
[8]  
Hansildaar R, 2020, LANCET RHEUMATOL
[9]  
Health Canada, UL FEB INCR RISK CAR UL FEB INCR RISK CAR
[10]   Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing [J].
Hershfield, M. S. ;
Callaghan, J. T. ;
Tassaneeyakul, W. ;
Mushiroda, T. ;
Thorn, C. F. ;
Klein, T. E. ;
Lee, M. T. M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (02) :153-158
123